Nebivolol Ratiopharm (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure: improves left‑ventricular function and reduces symptoms of chronic heart failure.
• Cardiovascular risk reduction: may decrease the incidence of stroke and myocardial infarction in high‑risk patients.

• Nebivolol selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, which reduces cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, further contributing to its antihypertensive effect.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Fatigue: feeling of reduced energy or tiredness.
• Nausea: mild stomach upset or queasiness.
• Bradycardia: slower than normal heart rate.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Atrioventricular block: impaired electrical conduction of the heart.
• Bronchospasm: tightening of airway muscles, especially in patients with asthma.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating Nebivolol, consider patient‑specific factors and monitor appropriately.

• Renal impairment: dose may need adjustment in reduced kidney function.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Asthma or COPD: monitor for bronchospasm, as β‑blockade can exacerbate airway narrowing.
• Concomitant AV‑nodal blockers: increased risk of profound bradycardia.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol may interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid)

• Other beta‑blockers: additive bradycardia and hypotension.
• Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block.
• Clonidine: abrupt discontinuation can cause rebound hypertension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance hypotensive effect.
• Diuretics: risk of orthostatic hypotension and electrolyte imbalance.
• Antidepressants (SSRIs, SNRIs): may affect nebivolol metabolism via CYP2D6.
• Antidiabetic agents: may mask hypoglycemia symptoms.